Beyond the limited efficacy in this study, other limitations of our study included a relatively small sample size at the RP2D (n = 6), lack of assessment of c-Met or other biomarkers on a more contemporary tumor specimen reflective of the metastatic phenotype, lack of pharmacodynamic modulation assessment for the combination of drugs, and the broad inclusion of any HER-2-positive disease. The gene discussed is ERBB2; the disease is neoplasm.